Leonard H. Wexler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leonard H. Wexler has a total of 256 co-authors. Here are the top co-authors by number of shared publications:
- Emily K. Slotkin
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
28 shared publications - Cristina R. Antonescu
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
22 shared publications - William D. Tap
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
18 shared publications - Paul A. Meyers
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
16 shared publications - Brian D. Crompton
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
13 shared publications - Josephine Kamtai Dermawan
Department of Pathology and Laboratory Medicine Cleveland Clinic Cleveland Ohio USA
13 shared publications
Latest Publications
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10  (4) , e2500909
Does Longitudinal Targeted Panel Sequencing Provide Clinically Relevant Information in Translocation-Associated Sarcomas?
PURPOSE: Translocation-associated sarcomas (TAS) represent a heterogeneous group of pathologic entities characterized by specific gene fusions and a low tumor mutational burden (TMB). Although RNA sequencing remains the hallmark molecular platform to establish the fusion type, targeted panel DNA next-generation sequencing (NGS) has been increasingly used in TAS to identify actionable alterations as well as potential mechanisms of resistance to therapy. MATERIALS AND METHODS: We herein investigate sequential targeted DNA sequencing (Memorial Sloan Kettering Cancer Center—Integrated Mutation Profiling of Actionable Cancer Targets) in a large cohort of 108 TAS, spanning six most common subtypes, with available longitudinal sequencing. RESULTS: Overall, 53% of cases acquired alterations (n = 122) compared with the initial testing, of which 33 (27%) were oncogenic/likely oncogenic. Only two of the five patients with >3 tests/each acquired oncogenic mutations. Overall, 21% of cases did not acquire alterations in any assay. Subsequent NGS was initiated after systemic treatment (93%) and disease progression (83%). The number of oncogenic acquired alterations did not correlate with histotype (mean 0.4/case). In sequential NGS, the mean mutation count, TMB, and fraction of genome altered were significantly higher ( P < .001, .04, and .03, respectively) compared with baseline. TP53 alteration was the most common acquired mutation (10%), being detected mostly in the subsequent assay. By contrast, other common alterations, such as STAG2 in Ewing sarcoma and gene amplifications in alveolar rhabdomyosarcoma, were detected at diagnosis. Although 27% of pathogenic alterations in the initial and 9% in the subsequent NGS were deemed as OncoKB levels 1-2 for other cancers, none were relevant for sarcomas. CONCLUSION: The role of multiple NGS testing in the context of TAS remains undetermined.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10  (4) , e2500909
Does Longitudinal Targeted Panel Sequencing Provide Clinically Relevant Information in Translocation-Associated Sarcomas?
PURPOSE: Translocation-associated sarcomas (TAS) represent a heterogeneous group of pathologic entities characterized by specific gene fusions and a low tumor mutational burden (TMB). Although RNA sequencing remains the hallmark molecular platform to establish the fusion type, targeted panel DNA next-generation sequencing (NGS) has been increasingly used in TAS to identify actionable alterations as well as potential mechanisms of resistance to therapy. MATERIALS AND METHODS: We herein investigate sequential targeted DNA sequencing (Memorial Sloan Kettering Cancer Center—Integrated Mutation Profiling of Actionable Cancer Targets) in a large cohort of 108 TAS, spanning six most common subtypes, with available longitudinal sequencing. RESULTS: Overall, 53% of cases acquired alterations (n = 122) compared with the initial testing, of which 33 (27%) were oncogenic/likely oncogenic. Only two of the five patients with >3 tests/each acquired oncogenic mutations. Overall, 21% of cases did not acquire alterations in any assay. Subsequent NGS was initiated after systemic treatment (93%) and disease progression (83%). The number of oncogenic acquired alterations did not correlate with histotype (mean 0.4/case). In sequential NGS, the mean mutation count, TMB, and fraction of genome altered were significantly higher ( P < .001, .04, and .03, respectively) compared with baseline. TP53 alteration was the most common acquired mutation (10%), being detected mostly in the subsequent assay. By contrast, other common alterations, such as STAG2 in Ewing sarcoma and gene amplifications in alveolar rhabdomyosarcoma, were detected at diagnosis. Although 27% of pathogenic alterations in the initial and 9% in the subsequent NGS were deemed as OncoKB levels 1-2 for other cancers, none were relevant for sarcomas. CONCLUSION: The role of multiple NGS testing in the context of TAS remains undetermined.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3  (2)
Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High-Dose Alkylator–Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
PURPOSE: Irinotecan and temozolomide (iT) have antitumor activity in relapsed Ewing sarcoma (ES). The purpose of this phase II trial was to evaluate whether iT added to an alkylator-intensified five-drug regimen (Ewing Family of Tumors [EFT]) improved the 4-year event free survival (EFS) for patients with newly diagnosed localized ES. METHODS: Patients with localized ES received six cycles of iT consolidation following completion of 21 weeks of EFT chemotherapy; patients with metastatic disease received 10 intercalated cycles of iT during EFT. The primary end point was 4-year EFS for patients with localized disease, with 85% and 70% of patients without events deemed promising and not promising, respectively. Secondary end points included EFS for metastatic patients, overall survival (OS), toxicity, and exploratory circulating tumor DNA analyses. RESULTS: Eighty-three patients were enrolled (46 localized, 37 metastatic; median age 16 years). The 4-year EFS for patients with localized disease was 76% (95% CI, 64% to 90%), which did not exceed the predefined threshold for unpromising efficacy. Among patients with metastatic disease, 4-year EFS was 56% (95% CI, 37% to 84%) for those with lung-only metastases and 43% (95% CI, 25% to 74%) for those with extrapulmonary metastases. Febrile neutropenia occurred in 96% of patients, most frequently following alkylator-containing cycles. Secondary malignancies developed in four patients. No unexpected toxicities were observed. CONCLUSION: The addition of iT to high-dose, alkylator-based up-front chemotherapy did not exceed the historical EFS benchmark in patients with radiographically localized ES.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3  (2)
Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High-Dose Alkylator–Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
PURPOSE: Irinotecan and temozolomide (iT) have antitumor activity in relapsed Ewing sarcoma (ES). The purpose of this phase II trial was to evaluate whether iT added to an alkylator-intensified five-drug regimen (Ewing Family of Tumors [EFT]) improved the 4-year event free survival (EFS) for patients with newly diagnosed localized ES. METHODS: Patients with localized ES received six cycles of iT consolidation following completion of 21 weeks of EFT chemotherapy; patients with metastatic disease received 10 intercalated cycles of iT during EFT. The primary end point was 4-year EFS for patients with localized disease, with 85% and 70% of patients without events deemed promising and not promising, respectively. Secondary end points included EFS for metastatic patients, overall survival (OS), toxicity, and exploratory circulating tumor DNA analyses. RESULTS: Eighty-three patients were enrolled (46 localized, 37 metastatic; median age 16 years). The 4-year EFS for patients with localized disease was 76% (95% CI, 64% to 90%), which did not exceed the predefined threshold for unpromising efficacy. Among patients with metastatic disease, 4-year EFS was 56% (95% CI, 37% to 84%) for those with lung-only metastases and 43% (95% CI, 25% to 74%) for those with extrapulmonary metastases. Febrile neutropenia occurred in 96% of patients, most frequently following alkylator-containing cycles. Secondary malignancies developed in four patients. No unexpected toxicities were observed. CONCLUSION: The addition of iT to high-dose, alkylator-based up-front chemotherapy did not exceed the historical EFS benchmark in patients with radiographically localized ES.
- Open Access
Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma
Despite comprehensive and multi-modal therapy, outcomes for children and adolescents with rhabdomyosarcoma (RMS) have plateaued over the past four decades. This is not for a lack of progress in the basic and translational studies of RMS. Indeed, advances in animal models and/or patient tissue sample acquisition and analysis have improved our understanding of RMS biology. Large-scale sequencing efforts have generated transcriptomic, genomic, and epigenomic datasets that highlight the heterogeneity of RMS and have the potential to improve prognostication and the application of precision medicine in patients with RMS. However, few of these discoveries have been clinically translated, and limitations to the accessibility, uniformity, and application of these new models and datasets hinder their utility. Here, we discuss how advances in understanding RMS biology, optimization of preclinical models, and strategies for translating basic science discoveries to the clinic can potentially improve outcomes for patients with RMS.
Open AccessBiological Advances and Current Challenges for Pediatric Rhabdomyosarcoma
Despite comprehensive and multi-modal therapy, outcomes for children and adolescents with rhabdomyosarcoma (RMS) have plateaued over the past four decades. This is not for a lack of progress in the basic and translational studies of RMS. Indeed, advances in animal models and/or patient tissue sample acquisition and analysis have improved our understanding of RMS biology. Large-scale sequencing efforts have generated transcriptomic, genomic, and epigenomic datasets that highlight the heterogeneity of RMS and have the potential to improve prognostication and the application of precision medicine in patients with RMS. However, few of these discoveries have been clinically translated, and limitations to the accessibility, uniformity, and application of these new models and datasets hinder their utility. Here, we discuss how advances in understanding RMS biology, optimization of preclinical models, and strategies for translating basic science discoveries to the clinic can potentially improve outcomes for patients with RMS.
- Open Access
- 27 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12  (9) , eaea6453
Single-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies in MYOD1 -mutant rhabdomyosarcoma
Myogenic differentiation 1 (MYOD1) L122R -mutant spindle cell rhabdomyosarcoma (SRMS) is an ultrarare, treatment-resistant sarcoma with dismal outcomes. We performed regulatory network analysis of single-nucleus RNA sequencing (snRNA-seq) from six patient tumors, revealing disrupted myogenesis and actionable master regulator (MR) dependencies across three coexisting tumor cell states, also conserved in patient-derived xenografts: (i) a MYOD1-enriched progenitor-like state, (ii) a proliferative transition state, and (iii) a partially differentiated state with reduced MYOD1 activity. Ligand-receptor analysis uncovered paracrine insulin-like growth factor 2 (IGF2)-IGF1 receptor (IGF1R)–phosphatidylinositol 3-kinase (PI3K) signaling from progenitor to transition/differentiated states, whose inhibition demonstrated therapeutic potential in ex vivo drug screens, and significantly improved disease control in a patient-derived xenograft model. Oncogenic MRs were recapitulated in 24 bulk RNA profiles, while 20 DNA profiles revealed recurrent IGF2/PI3K/AKT alterations, reinforcing shared transcriptional vulnerabilities. These findings characterize aberrant, mutant MYOD1–driven myogenesis sustained by IGF2 and nominate IGF1R-PI3K/AKT/mammalian target of rapamycin inhibitors for therapeutic translation in MYOD1 L122R -mutant SRMS, underscoring the utility of single-cell regulatory network analysis for uncovering actionable dependencies in rare, transcriptionally complex cancers.
- 27 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12  (9) , eaea6453
Open AccessSingle-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies in MYOD1 -mutant rhabdomyosarcoma
Myogenic differentiation 1 (MYOD1) L122R -mutant spindle cell rhabdomyosarcoma (SRMS) is an ultrarare, treatment-resistant sarcoma with dismal outcomes. We performed regulatory network analysis of single-nucleus RNA sequencing (snRNA-seq) from six patient tumors, revealing disrupted myogenesis and actionable master regulator (MR) dependencies across three coexisting tumor cell states, also conserved in patient-derived xenografts: (i) a MYOD1-enriched progenitor-like state, (ii) a proliferative transition state, and (iii) a partially differentiated state with reduced MYOD1 activity. Ligand-receptor analysis uncovered paracrine insulin-like growth factor 2 (IGF2)-IGF1 receptor (IGF1R)–phosphatidylinositol 3-kinase (PI3K) signaling from progenitor to transition/differentiated states, whose inhibition demonstrated therapeutic potential in ex vivo drug screens, and significantly improved disease control in a patient-derived xenograft model. Oncogenic MRs were recapitulated in 24 bulk RNA profiles, while 20 DNA profiles revealed recurrent IGF2/PI3K/AKT alterations, reinforcing shared transcriptional vulnerabilities. These findings characterize aberrant, mutant MYOD1–driven myogenesis sustained by IGF2 and nominate IGF1R-PI3K/AKT/mammalian target of rapamycin inhibitors for therapeutic translation in MYOD1 L122R -mutant SRMS, underscoring the utility of single-cell regulatory network analysis for uncovering actionable dependencies in rare, transcriptionally complex cancers.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3  (1)
Trastuzumab Deruxtecan Is Active in Desmoplastic Small Round Cell Tumor
PURPOSE: Desmoplastic small round cell tumor (DSRCT) is a rare sarcoma which remains almost universally fatal despite multimodality therapy. Human epidermal growth factor receptor 2 (HER2) has been identified as a potential therapeutic target prompting HER2-specific investigations and subsequent off-label treatment with fam-trastuzumab deruxtecan (T-DXd) in our DSRCT clinical cohort. METHODS: Fifty-two and 61 DSRCT patient samples were analyzed by immunohistochemical (IHC) assays and RNAseq, respectively. In addition, 19 patients at a single institution with DSRCT in need of therapy underwent IHC testing and RNAseq when feasible and received off-label T-DXd (monotherapy [n = 14], alternating with another agent [n = 2], concomitantly in combination [n = 2]; measurable disease [n = 17], adjuvant setting [n = 2]). RESULTS: HER2 expression levels by RNAseq were analyzed in the context of 346 patients with solid tumor and 23 histologies, with DSRCT having the third highest HER2 expression level overall and a median transcripts per million (TPM) expression level of 41.8 (range, 6.3-116.3). While TMA IHC analyses noted minimal HER2 IHC positivity using 4B5, IHC with clones 29D8 and CB11 uncovered 8.7- to 12.7-fold more HER2 reactivity, respectively. All 17 patients with measurable disease experienced clinical benefit (stable disease or partial response [PR]) with minimal toxicity. In addition, 9 of 17 patients achieved a RECIST PR (53% overall response rate). The response rate did not correlate with available IHC or RNAseq data, and some patients with no membranous IHC expression achieved PR. CONCLUSION: These data show that T-DXd is active in DSRCT and support the planned biomarker-agnostic formal clinical trial with the Children's Oncology Group.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3  (1)
Trastuzumab Deruxtecan Is Active in Desmoplastic Small Round Cell Tumor
PURPOSE: Desmoplastic small round cell tumor (DSRCT) is a rare sarcoma which remains almost universally fatal despite multimodality therapy. Human epidermal growth factor receptor 2 (HER2) has been identified as a potential therapeutic target prompting HER2-specific investigations and subsequent off-label treatment with fam-trastuzumab deruxtecan (T-DXd) in our DSRCT clinical cohort. METHODS: Fifty-two and 61 DSRCT patient samples were analyzed by immunohistochemical (IHC) assays and RNAseq, respectively. In addition, 19 patients at a single institution with DSRCT in need of therapy underwent IHC testing and RNAseq when feasible and received off-label T-DXd (monotherapy [n = 14], alternating with another agent [n = 2], concomitantly in combination [n = 2]; measurable disease [n = 17], adjuvant setting [n = 2]). RESULTS: HER2 expression levels by RNAseq were analyzed in the context of 346 patients with solid tumor and 23 histologies, with DSRCT having the third highest HER2 expression level overall and a median transcripts per million (TPM) expression level of 41.8 (range, 6.3-116.3). While TMA IHC analyses noted minimal HER2 IHC positivity using 4B5, IHC with clones 29D8 and CB11 uncovered 8.7- to 12.7-fold more HER2 reactivity, respectively. All 17 patients with measurable disease experienced clinical benefit (stable disease or partial response [PR]) with minimal toxicity. In addition, 9 of 17 patients achieved a RECIST PR (53% overall response rate). The response rate did not correlate with available IHC or RNAseq data, and some patients with no membranous IHC expression achieved PR. CONCLUSION: These data show that T-DXd is active in DSRCT and support the planned biomarker-agnostic formal clinical trial with the Children's Oncology Group.
- Open Access
- 22 December 2025
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 43  (1) , 47-53
Step-down management of fever and neutropenia in low-risk pediatric and adolescent-young adult oncology patients is safe and effective: a single center experience
Febrile neutropenia (FN) is a common complication in pediatric oncology patients that typically necessitates hospitalization for intravenous antibiotics, resulting in significant use of hospital resources and decreased patient and family quality of life. Recently several centers have published early discharge guidelines for patients with low-risk FN, but this has not yet been reported at large tertiary centers with high acuity. Here we describe implementation of a low-risk early discharge FN guideline at our tertiary cancer center with resulting decrease in median length of stay (2.39 days saved per early discharge encounter) and no adverse events, including sepsis or infection-related mortality.
- 22 December 2025
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 43  (1) , 47-53
Open AccessStep-down management of fever and neutropenia in low-risk pediatric and adolescent-young adult oncology patients is safe and effective: a single center experience
Febrile neutropenia (FN) is a common complication in pediatric oncology patients that typically necessitates hospitalization for intravenous antibiotics, resulting in significant use of hospital resources and decreased patient and family quality of life. Recently several centers have published early discharge guidelines for patients with low-risk FN, but this has not yet been reported at large tertiary centers with high acuity. Here we describe implementation of a low-risk early discharge FN guideline at our tertiary cancer center with resulting decrease in median length of stay (2.39 days saved per early discharge encounter) and no adverse events, including sepsis or infection-related mortality.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9  (9) , e2500603
Spectrum and Clinical Impact of Secondary Genetic Alterations in Translocation-Associated Sarcomas
PURPOSE: Translocation-associated sarcomas (TASs) encompass a wide spectrum of pathologic entities and clinical behavior. Driven by the oncogenic fusion, TASs typically show a stable genome and a low tumor mutational burden (TMB), with infrequent secondary genetic alterations (SGAs). Although oncogenic/likely oncogenic SGAs have been associated with an aggressive clinical course in certain histotypes, a comprehensive comparative study of their clinical impact across TAS histotypes has not been performed to date. MATERIALS AND METHODS: Herein, we investigate the genomic landscape of 632 TASs, spanning the most common histotypes: Ewing sarcoma (ES, n = 196), desmoplastic small round cell sarcoma (DSRCT, n = 115), solitary fibrous tumor (SFT, n = 87), synovial sarcoma (SS, n = 75), etc. All tumors were tested on a clinically validated, matched tumor-normal DNA-targeted next-generation sequencing panel, with confirmed gene fusion partners. Both gene-level and arm-level copy number alterations were assessed and correlated with survival. RESULTS: Overall, oncogenic SGAs were detected in 51% of patients, with the highest incidence in myxoid liposarcoma (MLS, 88%). Patients with oncogenic SGA had a higher TMB and were associated with distant metastasis and/or progression-free survival (PFS) in ES, SFT, SS, and MLS in the localized group. TP53 mutations were the most common oncogenic SGAs across histotypes, with SFT and ES showing the highest rate (26% and 11%) and associated with worse PFS and disease-specific survival ( P < .01). TP53 mutations in ES ( P < .01) and SFT ( P = .045) and TERT promoter mutations in SFT ( P < .001) and MLS ( P = .049) correlated with metastasis in the localized group. CONCLUSION: Overall, oncogenic SGA correlated with a worse survival in certain TAS types.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9  (9) , e2500603
Spectrum and Clinical Impact of Secondary Genetic Alterations in Translocation-Associated Sarcomas
PURPOSE: Translocation-associated sarcomas (TASs) encompass a wide spectrum of pathologic entities and clinical behavior. Driven by the oncogenic fusion, TASs typically show a stable genome and a low tumor mutational burden (TMB), with infrequent secondary genetic alterations (SGAs). Although oncogenic/likely oncogenic SGAs have been associated with an aggressive clinical course in certain histotypes, a comprehensive comparative study of their clinical impact across TAS histotypes has not been performed to date. MATERIALS AND METHODS: Herein, we investigate the genomic landscape of 632 TASs, spanning the most common histotypes: Ewing sarcoma (ES, n = 196), desmoplastic small round cell sarcoma (DSRCT, n = 115), solitary fibrous tumor (SFT, n = 87), synovial sarcoma (SS, n = 75), etc. All tumors were tested on a clinically validated, matched tumor-normal DNA-targeted next-generation sequencing panel, with confirmed gene fusion partners. Both gene-level and arm-level copy number alterations were assessed and correlated with survival. RESULTS: Overall, oncogenic SGAs were detected in 51% of patients, with the highest incidence in myxoid liposarcoma (MLS, 88%). Patients with oncogenic SGA had a higher TMB and were associated with distant metastasis and/or progression-free survival (PFS) in ES, SFT, SS, and MLS in the localized group. TP53 mutations were the most common oncogenic SGAs across histotypes, with SFT and ES showing the highest rate (26% and 11%) and associated with worse PFS and disease-specific survival ( P < .01). TP53 mutations in ES ( P < .01) and SFT ( P = .045) and TERT promoter mutations in SFT ( P < .001) and MLS ( P = .049) correlated with metastasis in the localized group. CONCLUSION: Overall, oncogenic SGA correlated with a worse survival in certain TAS types.
- Open Access
- 7 May 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9  (1) , 1-10
Germline pathogenic variants in DNA repair pathways: a key feature in a significant subset of translocation-associated sarcomas
Translocation-associated sarcomas (TAS) are rare, phenotypically heterogeneous, with predisposition for young adults. We aimed to investigate the clinical impact of germline pathogenic/likely pathogenic (P/LP) variants in a diverse group of TAS and to conduct a comprehensive comparative analysis of clinicopathologic features, genomic alterations, and survival outcomes. A retrospective cohort of 426 TAS patients with both tumor and germline DNA sequencing was investigated for clinical actionability of P/LP variants, and potential impact on current screening guidelines and clinical interventions. Twenty-eight patients (6.6%) carried Tier 1 germline P/LP variants (moderate to high penetrance autosomal dominant (AD) variants), while 27 (6.3%) patients carried Tier 2 variants (monoallelic autosomal recessive or low penetrance AD variants). Compared to Tier 2, Tier 1 patients were more commonly of European ancestry and had a higher frequency of first- and second-degree relatives with cancer history. Notably, the frequency of both tiers variants was lower among pediatric patients compared to older patients and differed across TAS histologies, with the highest observed in solitary fibrous tumors. All germline P/LP variants were monoallelic, dispersed across multiple genes, and enriched in DNA damage repair pathways. There was no association between the germline P/LP variants and somatic genomic profile, nor any survival impact when stratified by histotype. Our findings highlight the incidence of clinically significant germline P/LP variants in TAS is lower in pediatric patients, questioning current sarcoma genetic screening guidelines and supporting germline testing for all TAS patients. Significant interventions were triggered in 46% of Tier 1 (n = 13), including platinum-based chemotherapy and PARP inhibitors in two BRCA1/2 patients.
- 7 May 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9  (1) , 1-10
Open AccessGermline pathogenic variants in DNA repair pathways: a key feature in a significant subset of translocation-associated sarcomas
Translocation-associated sarcomas (TAS) are rare, phenotypically heterogeneous, with predisposition for young adults. We aimed to investigate the clinical impact of germline pathogenic/likely pathogenic (P/LP) variants in a diverse group of TAS and to conduct a comprehensive comparative analysis of clinicopathologic features, genomic alterations, and survival outcomes. A retrospective cohort of 426 TAS patients with both tumor and germline DNA sequencing was investigated for clinical actionability of P/LP variants, and potential impact on current screening guidelines and clinical interventions. Twenty-eight patients (6.6%) carried Tier 1 germline P/LP variants (moderate to high penetrance autosomal dominant (AD) variants), while 27 (6.3%) patients carried Tier 2 variants (monoallelic autosomal recessive or low penetrance AD variants). Compared to Tier 2, Tier 1 patients were more commonly of European ancestry and had a higher frequency of first- and second-degree relatives with cancer history. Notably, the frequency of both tiers variants was lower among pediatric patients compared to older patients and differed across TAS histologies, with the highest observed in solitary fibrous tumors. All germline P/LP variants were monoallelic, dispersed across multiple genes, and enriched in DNA damage repair pathways. There was no association between the germline P/LP variants and somatic genomic profile, nor any survival impact when stratified by histotype. Our findings highlight the incidence of clinically significant germline P/LP variants in TAS is lower in pediatric patients, questioning current sarcoma genetic screening guidelines and supporting germline testing for all TAS patients. Significant interventions were triggered in 46% of Tier 1 (n = 13), including platinum-based chemotherapy and PARP inhibitors in two BRCA1/2 patients.
- Open Access
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2  (2) , e2400095
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results
PURPOSE: We hypothesized that ACR-368 (prexasertib) would be active in desmoplastic small round cell tumor (DSRCT) because of favorable responses in preclinical models. METHODS: Preclinical work identified ACR-368 activity in DSRCT, and a phase I/II trial of ACR-368 and irinotecan in patients 12 months and older with relapsed/refractory DSRCT was conducted. The primary objectives were determination of recommended phase II dose (RP2D) and best overall response rate (ORR) at the RP2D in DSRCT, with ≥3 of 16 responses considered promising. RESULTS: Preclinical data confirmed ACR-368 as potentially therapeutic in DSRCT, and 19 patients were enrolled in a subsequent clinical trial. Treatment was well tolerated, and cytopenias were managed using growth factors. Fifteen of 19 patients, including five of six achieving PR, had previously received irinotecan. The estimated ORR at the RP2D was 23% (lower boundary one-sided 90% CI, 9%), exceeding the unpromising rate of 5%. In addition, three patients with DSRCT had a PR at doses other than the RP2D, bringing the ORR for all doses (n = 19) to 32% (90% CI, 15% to 53%). The median overall survival was 19 months (95% CI, 13 to 36). CONCLUSION: The RP2D of ACR-368 with irinotecan by age group is ACR-368 105 or 150 mg/m 2 once on day 1 (>21 years or ≤21 years, respectively) and irinotecan 15 mg/m 2 once daily for 5 days in 21-day cycles for both groups. The study met its primary objective to consider ACR-368 and irinotecan promising in DSRCT and, to our knowledge, is the first incorporating a targeted therapy to achieve this magnitude of response.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2  (2) , e2400095
Open AccessACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results
PURPOSE: We hypothesized that ACR-368 (prexasertib) would be active in desmoplastic small round cell tumor (DSRCT) because of favorable responses in preclinical models. METHODS: Preclinical work identified ACR-368 activity in DSRCT, and a phase I/II trial of ACR-368 and irinotecan in patients 12 months and older with relapsed/refractory DSRCT was conducted. The primary objectives were determination of recommended phase II dose (RP2D) and best overall response rate (ORR) at the RP2D in DSRCT, with ≥3 of 16 responses considered promising. RESULTS: Preclinical data confirmed ACR-368 as potentially therapeutic in DSRCT, and 19 patients were enrolled in a subsequent clinical trial. Treatment was well tolerated, and cytopenias were managed using growth factors. Fifteen of 19 patients, including five of six achieving PR, had previously received irinotecan. The estimated ORR at the RP2D was 23% (lower boundary one-sided 90% CI, 9%), exceeding the unpromising rate of 5%. In addition, three patients with DSRCT had a PR at doses other than the RP2D, bringing the ORR for all doses (n = 19) to 32% (90% CI, 15% to 53%). The median overall survival was 19 months (95% CI, 13 to 36). CONCLUSION: The RP2D of ACR-368 with irinotecan by age group is ACR-368 105 or 150 mg/m 2 once on day 1 (>21 years or ≤21 years, respectively) and irinotecan 15 mg/m 2 once daily for 5 days in 21-day cycles for both groups. The study met its primary objective to consider ACR-368 and irinotecan promising in DSRCT and, to our knowledge, is the first incorporating a targeted therapy to achieve this magnitude of response.